Novo Nordisk has secured a permanent injunction restricting LifeRxMD from making certain claims involving Ozempic, Wegovy and Rybelsus in its marketing of compounded drugs.
The injunction was entered as part of a confidential settlement between Novo Nordisk and LifeRxMD, according to a Sept. 2 final judgment in the U.S. District Court for the District of New Jersey. Novo Nordisk had alleged that LifeRxMD’s marketing falsely suggested its compounded products were genuine, FDA-approved or reviewed, or associated with or equivalent to Novo Nordisk’s products. LifeRxMD denied the allegations.
Under the injunction, LifeRxMD is restricted from using Novo Nordisk’s trademarks in certain ways when advertising or selling compounded drugs.
For 12 months, LifeRxMD must also disclose that compounded drugs it markets are not FDA-approved or reviewed for safety, effectiveness or quality and that FDA-approved semaglutide medicines are available.
The LifeRxMD settlement is the latest in a series of legal actions by the two brand-name GLP-1 makers this year. Eli Lilly filed a lawsuit against six companies in August, accusing them of illegally selling its unapproved investigational drug retatrutide. The company has also referred more than 200 entities to federal and state authorities.
The LifeRxMD outcome also follows a settlement Novo Nordisk reached earlier in 2026 with Hims & Hers. Novo Nordisk sued the telehealth company over patent infringement in February after it began selling a compounded Wegovy pill. The two sides then struck a partnership the following month.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
